Skip to main content
SpringerLink
Log in

Pathophysiology and Immunology of Chronic Graft-Versus-Host Disease

  • Chapter
  • First Online:
Atlas of Graft-versus-Host Disease

  • 1143 Accesses

Abstract

Chronic graft-versus-host disease (cGVHD) is the leading cause of late morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) [1, 2].Chronic GVHD and its associated complications result in increased resource utilization, poor quality of life parameters, and decreased overall survival in patients. Early detection and appropriate intervention will help in improving long-term outcomes of HCT patients. Detection of biomarkers in blood or involved tissue (skin, gut, etc.) may help in early diagnosis and risk-stratification of patients, thereby impacting the type and intensity of immunosuppressive therapy chosen. To date, early intervention and successful treatment of cGVHD patients has lagged due to difficulty in scoring organ involvement due to lack of uniform and objective scoring tools. Another major problem in the field is the absence of approved therapies in the steroid refractory setting, which is a result of the difficulties of clinical trials in this patient population due to poor standardization of scoring systems and evaluation of objective responses. There are other competing causes of death, including disease relapse and infectious complications that may confound survival data. Establishment of standardized cGVHD scoring systems has helped enormously in staging the disease and evaluating responses to new therapies, thereby helping to make objective response evaluations possible [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Jaglowski SM, Devine SM. Graft-versus-host disease: why have we not made more progress? Curr Opin Hematol. 2014;21(2):141–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984–9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340–52.

    Article  CAS  PubMed  Google Scholar 

  5. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12(2):126–37.

    Article  PubMed  Google Scholar 

  6. Pidala J, Sarwal M, Roedder S, Lee SJ. Biologic markers of chronic GVHD. Bone Marrow Transplant. 2014;49(3):324–31.

    Article  CAS  PubMed  Google Scholar 

  7. Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT, et al. Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood. 2004;103(10):3986–8.

    Article  CAS  PubMed  Google Scholar 

  8. Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic R, et al. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. Biol Blood Marrow Transplant. 2006;12(1 Suppl 2):22–30.

    Article  PubMed  Google Scholar 

  9. Fukunaga A, Ishikawa T, Kishihata M, Shindo T, Hori T, Uchiyama T. Altered homeostasis of CD4(+) memory T cells in allogeneic hematopoietic stem cell transplant recipients: chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell pool. Biol Blood Marrow Transplant. 2007;13(10):1176–84.

    Article  PubMed  Google Scholar 

  10. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106(8):2903–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412–5.

    Article  CAS  PubMed  Google Scholar 

  12. Abrahamsen IW, Somme S, Heldal D, Egeland T, Kvale D, Tjonnfjord GE. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica. 2005;90(1):86–93.

    PubMed  Google Scholar 

  13. Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, Andrè V, et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation. 2009;88(11):1261–72.

    Article  CAS  PubMed  Google Scholar 

  14. Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana P, Krailo M, et al. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children’s Oncology Group Study ASCT0031. Biol Blood Marrow Transplant. 2011;17(12):1804–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pratt LM, Liu Y, Ugarte-Torres A, Hoegh-Petersen M, Podgorny PJ, Lyon AW, et al. IL 15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. Bone Marrow Transplant. 2013;48(5):722–8.

    Article  CAS  PubMed  Google Scholar 

  16. Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 2014;123(5):786–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood. 2012;120(12):2529–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med. 1992;327(23):1613–7.

    Article  CAS  PubMed  Google Scholar 

  19. Das H, Imoto S, Murayama T, Mizuno I, Sugimoto T, Taniguchi R, et al. Kinetic analysis of cytokine gene expression in patients with GVHD after donor lymphocyte infusion. Bone Marrow Transplant. 2001;27(4):373–80.

    Article  CAS  PubMed  Google Scholar 

  20. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324(10):667–74.

    Article  CAS  PubMed  Google Scholar 

  21. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol. 1993;23(2):333–7.

    Article  CAS  PubMed  Google Scholar 

  22. Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol. 2001;13(5):275–82.

    Article  CAS  PubMed  Google Scholar 

  23. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft vs. host disease. Blood. 2016. pii: blood-2016-02-702852. [Epub ahead of print].

    Google Scholar 

  25. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra143.

    Article  Google Scholar 

  26. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2007;13(4):386–97.

    Article  CAS  Google Scholar 

  27. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105(5):2227–34.

    Article  CAS  PubMed  Google Scholar 

  28. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol. 2006;18(5):276–83.

    Article  CAS  PubMed  Google Scholar 

  29. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group. Blood. 2008;111(6):3276–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110(1):237–41.

    Article  CAS  PubMed  Google Scholar 

  32. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol. 2005;27(4):247–9.

    Article  CAS  PubMed  Google Scholar 

  33. Nakasone H, Tian L, Sahaf B, Kawase T, Schoenrock K, Perloff S, et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood. 2015;125(20):3193–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122(8):1510–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. SD S, J F, Nguyen H, Bastian D, Heinriches J, Y W, et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. PloS One. 2015;10(9):e0137641.

    Article  Google Scholar 

  36. Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015;125(26):4085–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, et al. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol. 2016. pii: JCO659615.

    Google Scholar 

  38. Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(12):1862–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98(5):1594–600.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA

    Amandeep Salhotra

  2. Division of Dermatology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Ryotaro Nakamura

Authors
  1. Amandeep Salhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryotaro Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amandeep Salhotra .

Editor information

Editors and Affiliations

  1. Division of Dermatology, City of Hope National Medical Center Division of Dermatology, Durante, California, USA

    Jonathan A. Cotliar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Salhotra, A., Nakamura, R. (2017). Pathophysiology and Immunology of Chronic Graft-Versus-Host Disease. In: Cotliar, J. (eds) Atlas of Graft-versus-Host Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-46952-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46952-2_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-46950-8

  • Online ISBN: 978-3-319-46952-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation